Drug Development for Urgent Medical Needs

IHP Therapeutics is focused on developing IHP-102, a novel therapeutic aimed at treating acute vaso-occlusive crises in patients with sickle cell disease. This innovative treatment functions as a dual inhibitor of P-selectin and complement pathways, which are critical in the mechanisms leading to vaso-occlusion. By targeting these pathways, IHP-102 has the potential to not only alleviate pain during crises but also to mitigate the associated tissue and organ damage, thereby offering a disease-modifying effect. The goal of this self-administered rescue therapeutic is to empower individuals with sickle cell disease, allowing them to manage their condition at home and reducing reliance on traditional healthcare systems.

The development of IHP-102 represents a significant advancement in the management of sickle cell disease, as it aims to provide a more accessible and effective treatment option. By moving care into the home setting, IHP Therapeutics seeks to improve patient outcomes and quality of life while also addressing the challenges posed by costly and often inadequate healthcare facilities. This approach not only emphasizes patient empowerment but also highlights the company's commitment to innovative solutions in the biotech field.

United States

IHP Therapeuticsis developing IHP-009, a Phase 3 ready new molecule to treat patients hospitalized with COVID-19.The company is also working on novel carbohydrate-based drugs to treat inflammation and the pathologies of infectious diseases.

IHP Therapeutics

Company Details